The Point of Care Diagnostics Market was estimated around USD 24,800 million in 2019 and expected to grow at a CAGR of 10.3% over the forecast period (2020-2027).

More Info, Click to Access Complete Report – https://www.gmiresearch.com/report/global-point-of-care-poc-equipment-market/

The factors driving growth of the Point of Care Diagnostics Market includes increasing prevalence of diabetes, cardiovascular disorders, and infectious diseases, rise in government expenditure on enhancing healthcare infrastructure, growing demand for telehealth services and improvements in the living standards. For instance, almost 206 million people are living with diabetes, this figure is predicted to reach 238 million by the end of 2030 and 260 million by 2045 and over 1 in 2 adults living with diabetes are undiagnosed, which will push the demand for point of care diagnostics solutions in the approaching years. Moreover, growing awareness amongst people about early diagnosis of diseases, increasing adoption of digital technologies by manufacturers, rise in the launch of innovative products, and rapid urbanization, are some of the additional factors supplementing the Global Point of Care Diagnostics Market. In addition, the increasing investments by major companies on research and development, strategic partnerships, and collaborations between key industry leaders, rising disposable incomes and growing population growth rates, are further propelling the Point of Care Diagnostics Market Size.

However, growth of the Point of Care Diagnostics Market is hindered attributed to its high cost.

The prominent players operating in the market are EKF Diagnostics, Siemens Healthcare Private Limited, BD, Abbott, Danaher, Quidel Corporation, Chembio Diagnostics, Inc., F. Hoffmann-La Roche Ltd, Trinity Biotech and Johnson & Johnson Services, Inc., among others.

Based on Platform, the Lateral Flow Assays segment is predicted to grow at a significant CAGR during the forecast period

The lateral flow assays avoid lengthy and conventional laboratory procedures, and are cost-effective, are some of the factors propelling segment’s growth. 

Based on Product, the Glucose Monitoring Products segment is projected to expand at a remarkable CAGR over the forecast period

Increasing prevalence of diabetes across the globe and technological innovations in glucose monitoring devices, are pushing segment’s growth.

Based on Region, the North America region is expected to increase at a robust CAGR during the forecast period

As per the Point of Care Diagnostics Market Analysis, increasing prevalence of diabetes and cardiovascular diseases across United States and Canada, technological advancements in glucose monitoring devices and high disposable income, are driving the market growth in North America.

Key Developments

  • In 2020, BD, introduced a portable, rapid, point-of-care SARS-CoV-2 diagnostic test to be used with the company’s Veritor Plus system to identify SARS-CoV-2. This assay can provide results in 15 minutes and is a highly portable instrument.
  • In 2019, Chembio Diagnostics, Inc. entered into a strategic alliance with Shire Human Genetic Therapies, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. The companies planned to develop a POC diagnostic test to identify an undisclosed biomarker.

Market Segmentation

Segmentation by Platform

  • Dipsticks
  • Lateral Flow Assays
  • Molecular Diagnostics
  • Microfluidics
  • Immunoassays

Segmentation by Mode of Purchase

  • OTC Products
  • Prescription-Based Products

Segmentation by Product

  • Cardiometabolic Monitoring Products
    • Blood Gas/Electrolyte Testing Products
    • Cardiac Marker Testing Products
    • Hba1c Testing Products
  • Glucose Monitoring Products
    • Meters
    • Strips
    • Lancets & Lancing Devices
  • Infectious Disease Testing Products
    • HIV Testing Products
    • Influenza Testing Products
    • Sexually Transmitted Disease Testing Products
    • Hepatitis C Testing Products
    • Respiratory Infection Testing Products
    • Healthcare-Associated Infection Testing Products
    • Tropical Disease Testing Products
    • Other Infectious Disease Testing Products
  • Coagulation Monitoring Products
    • Act/Aptt Testing Products
    • Pt/Inr Testing Products
  • Tumor/Cancer Marker Testing Products
  • Pregnancy & Fertility Testing Products
    • Fertility Testing Products
    • Pregnancy Testing Products
  • Cholesterol Testing Products
  • Urinalysis Testing Products
  • Drugs-of-Abuse Testing Products
  • Hematology Testing Products
  • Fecal Occult Testing Products
  • Other POC Products

Segmentation by End User

  • Hospitals/Critical Care Centers
  • Professional Diagnostic Centers
  • Research Laboratories
  • Home Care Settings
  • Other End Users

Segmentation by Region

  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of APAC
  • North America
    • United States of America
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Spain
    • Rest of Europe
  • RoW
    • Brazil
    • South Africa
    • Saudi Arabia
    • UAE

About GMI Research

GMI Research is a market research and consulting firm which provides market insights and intelligence across 12 major sectors helping our clients in making effective investment and business decisions.

Media Contact
Company Name: GMI RESEARCH
Contact Person: Sarah Nash
Email: [email protected]
Phone: Europe – +353 1 442 8820; US – +1 860 881 2270
Address: Dublin, Ireland
Website: https://www.gmiresearch.com/